Skip to content
Bending the Curve Trial by Trial
?

Back to Rectal cancer

References: Rectal cancer

133 sources cited on this page. Links open the primary source.

  1. Ernest Miles W. A method of performing abdomino-perineal excision for carcinoma of the rectum and of the terminal portion of the pelvic colon. The Lancet. 1908;172(4451):1812-1813. DOI
    CiteLoading…
  2. Dukes CE. The classification of cancer of the rectum. The Journal of Pathology and Bacteriology. 1932;35(3):323-332. DOI
    CiteLoading…
  3. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?. Br J Surg. 1982;69(10):613-6. PubMedDOI
    CiteLoading…
  4. Buess G, Theiss R, Hutterer F, Pichlmaier H, Pelz C, Holfeld T, et al. [Transanal endoscopic surgery of the rectum - testing a new method in animal experiments]. Leber Magen Darm. 1983;13(2):73-7. PubMed
    CiteLoading…
  5. Buess G, Hutterer F, Theiss J, Böbel M, Isselhard W, Pichlmaier H. [A system for a transanal endoscopic rectum operation]. Chirurg. 1984;55(10):677-80. PubMed
    CiteLoading…
  6. Buess G, Theiss R, Günther M, Hutterer F, Pichlmaier H. Endoscopic surgery in the rectum. Endoscopy. 1985;17(1):31-5. PubMedDOI
    CiteLoading…
  7. Buess G, Theiss R, Günther M, Hutterer F, Pichlmaier H. [Transanal endoscopic microsurgery]. Leber Magen Darm. 1985;15(6):271-9. PubMed
    CiteLoading…
  8. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;1(8496):1479-82. PubMedDOI
    CiteLoading…
  9. Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet. 1986;2(8514):996-9. PubMedDOI
    CiteLoading…
  10. Buess G, Kipfmüller K, Naruhn M, Braunstein S, Junginger T. Endoscopic microsurgery of rectal tumors. Endoscopy. 1987;19 Suppl 1:38-42. PubMedDOI
    CiteLoading…
  11. Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. Lancet. 1987;1(8545):1303-6. PubMedDOI
    CiteLoading…
  12. Swedish Rectal Cancer Trial, Cedermark B, Dahlberg M, Glimelius B, Påhlman L, Rutqvist LE, Wilking N. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336(14):980-7. PubMedDOI
    CiteLoading…
  13. Beets-Tan RG, Beets GL, Vliegen RF, Kessels AG, Van Boven H, De Bruine A, et al. Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet. 2001;357(9255):497-504. PubMedDOI
    CiteLoading…
  14. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638-46. PubMedDOI
    CiteLoading…
  15. Sobin LH. TNM: evolution and relation to other prognostic factors. Semin Surg Oncol. 2003;21(1):3-7. PubMedDOI
    CiteLoading…
  16. Wiley MJ, Rieger N. Audit and the birth of the abdomino-perineal excision for carcinoma of the rectum. ANZ J Surg. 2003;73(10):858-61. PubMedDOI
    CiteLoading…
  17. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Pudełko M, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol. 2004;72(1):15-24. PubMedDOI
    CiteLoading…
  18. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711-7; discussion 717-8. PubMedDOI
    CiteLoading…
  19. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731-40. PubMedDOI
    CiteLoading…
  20. Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23(24):5644-50. PubMedDOI
    CiteLoading…
  21. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114-23. PubMedDOI
    CiteLoading…
  22. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93(10):1215-23. PubMedDOI
    CiteLoading…
  23. Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620-5. PubMedDOI
    CiteLoading…
  24. MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ. 2006;333(7572):779. PubMedDOI
    CiteLoading…
  25. MERCURY Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology. 2007;243(1):132-9. PubMedDOI
    CiteLoading…
  26. Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246(5):693-701. PubMedDOI
    CiteLoading…
  27. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373(9666):811-20. PubMedDOI
    CiteLoading…
  28. Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28(10):1638-44. PubMedDOI
    CiteLoading…
  29. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29(20):2773-80. PubMedDOI
    CiteLoading…
  30. Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol. 2011;29(28):3753-60. PubMedDOI
    CiteLoading…
  31. Taylor FG, Quirke P, Heald RJ, Moran B, Blomqvist L, Swift I, et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg. 2011;253(4):711-9. PubMedDOI
    CiteLoading…
  32. van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12(6):575-82. PubMedDOI
    CiteLoading…
  33. Bonnetain F, Bosset JF, Gerard JP, Calais G, Conroy T, Mineur L, et al. What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?. Eur J Cancer. 2012;48(12):1781-90. PubMedDOI
    CiteLoading…
  34. Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne PL, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30(36):4558-65. PubMedDOI
    CiteLoading…
  35. Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012;30(31):3827-33. PubMedDOI
    CiteLoading…
  36. Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13(7):679-87. PubMedDOI
    CiteLoading…
  37. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926-33. PubMedDOI
    CiteLoading…
  38. van der Pas MH, Haglind E, Cuesta MA, Fürst A, Lacy AM, Hop WC, et al. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncol. 2013;14(3):210-8. PubMedDOI
    CiteLoading…
  39. Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15(2):184-90. PubMedDOI
    CiteLoading…
  40. Glynne-Jones R, Counsell N, Quirke P, Mortensen N, Maraveyas A, Meadows HM, et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol. 2014;25(7):1356-1362. PubMedDOI
    CiteLoading…
  41. Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014;15(11):1245-53. PubMedDOI
    CiteLoading…
  42. Jeong SY, Park JW, Nam BH, Kim S, Kang SB, Lim SB, et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15(7):767-74. PubMedDOI
    CiteLoading…
  43. O'Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;32(18):1927-34. PubMedDOI
    CiteLoading…
  44. Taylor FG, Quirke P, Heald RJ, Moran BJ, Blomqvist L, Swift IR, et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol. 2014;32(1):34-43. PubMedDOI
    CiteLoading…
  45. Allegra CJ, Yothers G, O'Connell MJ, Beart RW, Wozniak TF, Pitot HC, et al. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. J Natl Cancer Inst. 2015;107(11). PubMedDOI
    CiteLoading…
  46. Bonjer HJ, Deijen CL, Abis GA, Cuesta MA, van der Pas MH, de Lange-de Klerk ES, et al. A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med. 2015;372(14):1324-32. PubMedDOI
    CiteLoading…
  47. Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(2):200-7. PubMedDOI
    CiteLoading…
  48. Fleshman J, Branda M, Sargent DJ, Boller AM, George V, Abbas M, et al. Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial. JAMA. 2015;314(13):1346-55. PubMedDOI
    CiteLoading…
  49. Garcia-Aguilar J, Renfro LA, Chow OS, Shi Q, Carrero XW, Lynn PB, et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol. 2015;16(15):1537-1546. PubMedDOI
    CiteLoading…
  50. Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979-89. PubMedDOI
    CiteLoading…
  51. Saclarides TJ. Transanal Endoscopic Microsurgery. Clin Colon Rectal Surg. 2015;28(3):165-75. PubMedDOI
    CiteLoading…
  52. Stevenson AR, Solomon MJ, Lumley JW, Hewett P, Clouston AD, Gebski VJ, et al. Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer: The ALaCaRT Randomized Clinical Trial. JAMA. 2015;314(13):1356-63. PubMedDOI
    CiteLoading…
  53. Bujko K, Wyrwicz L, Rutkowski A, Malinowska M, Pietrzak L, Kryński J, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016;27(5):834-42. PubMedDOI
    CiteLoading…
  54. Lirici MM, Hüscher CG. Techniques and technology evolution of rectal cancer surgery: a history of more than a hundred years. Minim Invasive Ther Allied Technol. 2016;25(5):226-33. PubMedDOI
    CiteLoading…
  55. Saito S, Fujita S, Mizusawa J, Kanemitsu Y, Saito N, Kinugasa Y, et al. Male sexual dysfunction after rectal cancer surgery: Results of a randomized trial comparing mesorectal excision with and without lateral lymph node dissection for patients with lower rectal cancer: Japan Clinical Oncology Group Study JCOG0212. Eur J Surg Oncol. 2016;42(12):1851-1858. PubMedDOI
    CiteLoading…
  56. Azria D, Doyen J, Jarlier M, Martel-Lafay I, Hennequin C, Etienne P, et al. Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer. Ann Oncol. 2017;28(10):2436-2442. PubMedDOI
    CiteLoading…
  57. Erlandsson J, Holm T, Pettersson D, Berglund Å, Cedermark B, Radu C, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017;18(3):336-346. PubMedDOI
    CiteLoading…
  58. Fujita S, Mizusawa J, Kanemitsu Y, Ito M, Kinugasa Y, Komori K, et al. Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage II/III Lower Rectal Cancer (JCOG0212): A Multicenter, Randomized Controlled, Noninferiority Trial. Ann Surg. 2017;266(2):201-207. PubMedDOI
    CiteLoading…
  59. Jayne D, Pigazzi A, Marshall H, Croft J, Corrigan N, Copeland J, et al. Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer: The ROLARR Randomized Clinical Trial. JAMA. 2017;318(16):1569-1580. PubMedDOI
    CiteLoading…
  60. Rullier E, Rouanet P, Tuech JJ, Valverde A, Lelong B, Rivoire M, et al. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial. Lancet. 2017;390(10093):469-479. PubMedDOI
    CiteLoading…
  61. Ito M, Kobayashi A, Fujita S, Mizusawa J, Kanemitsu Y, Kinugasa Y, et al. Urinary dysfunction after rectal cancer surgery: Results from a randomized trial comparing mesorectal excision with and without lateral lymph node dissection for clinical stage II or III lower rectal cancer (Japan Clinical Oncology Group Study, JCOG0212). Eur J Surg Oncol. 2018;44(4):463-468. PubMedDOI
    CiteLoading…
  62. van der Valk MJM, Hilling DE, Bastiaannet E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391(10139):2537-2545. PubMedDOI
    CiteLoading…
  63. Fleshman J, Branda ME, Sargent DJ, Boller AM, George VV, Abbas MA, et al. Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial. Ann Surg. 2019;269(4):589-595. PubMedDOI
    CiteLoading…
  64. Fokas E, Allgäuer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, et al. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. J Clin Oncol. 2019;37(34):3212-3222. PubMedDOI
    CiteLoading…
  65. Hong YS, Kim SY, Lee JS, Nam BH, Kim KP, Kim JE, et al. Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial. J Clin Oncol. 2019;37(33):3111-3123. PubMedDOI
    CiteLoading…
  66. Ogura A, Konishi T, Cunningham C, Garcia-Aguilar J, Iversen H, Toda S, et al. Neoadjuvant (Chemo)radiotherapy With Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recurrence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients With Low cT3/4 Rectal Cancer. J Clin Oncol. 2019;37(1):33-43. PubMedDOI
    CiteLoading…
  67. Stevenson ARL, Solomon MJ, Brown CSB, Lumley JW, Hewett P, Clouston AD, et al. Disease-free Survival and Local Recurrence After Laparoscopic-assisted Resection or Open Resection for Rectal Cancer: The Australasian Laparoscopic Cancer of the Rectum Randomized Clinical Trial. Ann Surg. 2019;269(4):596-602. PubMedDOI
    CiteLoading…
  68. Rullier E, Vendrely V, Asselineau J, Rouanet P, Tuech JJ, Valverde A, et al. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial. Lancet Gastroenterol Hepatol. 2020;5(5):465-474. PubMedDOI
    CiteLoading…
  69. Tsukamoto S, Fujita S, Ota M, Mizusawa J, Shida D, Kanemitsu Y, et al. Long-term follow-up of the randomized trial of mesorectal excision with or without lateral lymph node dissection in rectal cancer (JCOG0212). Br J Surg. 2020;107(5):586-594. PubMedDOI
    CiteLoading…
  70. van Oostendorp SE, Belgers HJ, Bootsma BT, Hol JC, Belt EJTH, Bleeker W, et al. Locoregional recurrences after transanal total mesorectal excision of rectal cancer during implementation. Br J Surg. 2020;107(9):1211-1220. PubMedDOI
    CiteLoading…
  71. Wasmuth HH, Faerden AE, Myklebust TÅ, Pfeffer F, Norderval S, Riis R, et al. Transanal total mesorectal excision for rectal cancer has been suspended in Norway. Br J Surg. 2020;107(1):121-130. PubMedDOI
    CiteLoading…
  72. Bach SP, Gilbert A, Brock K, Korsgen S, Geh I, Hill J, et al. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study. Lancet Gastroenterol Hepatol. 2021;6(2):92-105. PubMedDOI
    CiteLoading…
  73. Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29-42. PubMedDOI
    CiteLoading…
  74. Conroy T, Bosset JF, Etienne PL, Rio E, François É, Mesgouez-Nebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(5):702-715. PubMedDOI
    CiteLoading…
  75. Des Guetz G, Landre T, Bollet MA, Mathonnet M, Quéro L. Is There a Benefit of Oxaliplatin in Combination with Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer? An Updated Meta-Analysis. Cancers (Basel). 2021;13(23). PubMedDOI
    CiteLoading…
  76. EMA. Jemperli (dostarlimab): European public assessment report page (opinion adopted 25/02/2021; marketing authorisation issued 21/04/2021), accessed 21 October 2026. Source
  77. Erlandsson J, Fuentes S, Radu C, Frödin JE, Johansson H, Brandberg Y, et al. Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm III trial. BJS Open. 2021;5(6). PubMedDOI
    CiteLoading…
  78. Park JW, Kang SB, Hao J, Lim SB, Choi HS, Kim DW, et al. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial. Lancet Gastroenterol Hepatol. 2021;6(7):569-577. PubMedDOI
    CiteLoading…
  79. Roodbeen SX, Penna M, van Dieren S, Moran B, Tekkis P, Tanis PJ, et al. Local Recurrence and Disease-Free Survival After Transanal Total Mesorectal Excision: Results From the International TaTME Registry. J Natl Compr Canc Netw. 2021;19(11):1232-1240. PubMedDOI
    CiteLoading…
  80. Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med. 2022;386(25):2363-2376. PubMedDOI
    CiteLoading…
  81. Feng Q, Yuan W, Li T, Tang B, Jia B, Zhou Y, et al. Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): short-term outcomes of a multicentre randomised controlled trial. Lancet Gastroenterol Hepatol. 2022;7(11):991-1004. PubMedDOI
    CiteLoading…
  82. Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer GG, Fietkau R, et al. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncol. 2022;8(1):e215445. PubMedDOI
    CiteLoading…
  83. Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM, et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J Clin Oncol. 2022;40(23):2546-2556. PubMedDOI
    CiteLoading…
  84. Gilbert A, Homer V, Brock K, Korsgen S, Geh I, Hill J, et al. Quality-of-life outcomes in older patients with early-stage rectal cancer receiving organ-preserving treatment with hypofractionated short-course radiotherapy followed by transanal endoscopic microsurgery (TREC): non-randomised registry of patients unsuitable for total mesorectal excision. Lancet Healthy Longev. 2022;3(12):e825-e838. PubMedDOI
    CiteLoading…
  85. Jin J, Tang Y, Hu C, Jiang LM, Jiang J, Li N, et al. Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR). J Clin Oncol. 2022;40(15):1681-1692. PubMedDOI
    CiteLoading…
  86. Xue X, Lin G. Transanal endoscopic microsurgery: exploring its indications and novel applications. A narrative review. Wideochir Inne Tech Maloinwazyjne. 2022;17(1):95-103. PubMedDOI
    CiteLoading…
  87. Basch E, Dueck AC, Mitchell SA, Mamon H, Weiser M, Saltz L, et al. Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048). J Clin Oncol. 2023;41(21):3724-3734. PubMedDOI
    CiteLoading…
  88. Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10-32. PubMedDOI
  89. Dijkstra EA, Nilsson PJ, Hospers GAP, Bahadoer RR, Meershoek-Klein Kranenbarg E, Roodvoets AGH, et al. Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial. Ann Surg. 2023;278(4):e766-e772. PubMedDOI
    CiteLoading…
  90. Gerard JP, Barbet N, Schiappa R, Magné N, Martel I, Mineur L, et al. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2023;8(4):356-367. PubMedDOI
    CiteLoading…
  91. Riis RN, Riis MH, Benth JŠ, Augestad KM. Beyond the transanal total mesorectal excision moratorium: local and distant recurrence among patients operated for low rectal tumours-5-year follow-up from a Norwegian University Hospital. Br J Surg. 2023;110(11):1547-1548. PubMedDOI
    CiteLoading…
  92. Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL, et al. Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023;389(4):322-334. PubMedDOI
    CiteLoading…
  93. Serra-Aracil X, Pericay C, Badia-Closa J, Golda T, Biondo S, Hernández P, et al. Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study). Ann Oncol. 2023;34(1):78-90. PubMedDOI
    CiteLoading…
  94. Sun Myint A, Rao C, Barbet N, Thamphya B, Pace-Loscos T, Schiappa R, et al. The safety and efficacy of total mesorectal excision (TME) surgery following dose-escalation: Surgical outcomes from the organ preservation in early rectal adenocarcinoma (OPERA) trial, a European multicentre phase 3 randomised trial (NCT02505750). Colorectal Dis. 2023;25(11):2160-2169. PubMedDOI
    CiteLoading…
  95. Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, et al. NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22(6):366-375. PubMedDOI
  96. Conroy T, Castan F, Etienne PL, Rio E, Mesgouez-Nebout N, Evesque L, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Ann Oncol. 2024;35(10):873-881. PubMedDOI
    CiteLoading…
  97. Green K. Dukes' classification. EBSCO Research Starters, Health and Medicine, 2024. Accessed 20 October 2026. Source
  98. Lin ZY, Zhang P, Chi P, Xiao Y, Xu XM, Zhang AM, et al. Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial. Ann Oncol. 2024;35(10):882-891. PubMedDOI
    CiteLoading…
  99. Scott AJ, Kennedy EB, Berlin J, Brown G, Chalabi M, Cho MT, et al. Management of Locally Advanced Rectal Cancer: ASCO Guideline. J Clin Oncol. 2024;42(28):3355-3375. PubMedDOI
  100. Verheij FS, Omer DM, Williams H, Lin ST, Qin LX, Buckley JT, et al. Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial. J Clin Oncol. 2024;42(5):500-506. PubMedDOI
    CiteLoading…
  101. Baron D, Pace Loscos T, Schiappa R, Barbet N, Dost E, Ben Dhia S, et al. A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial. Ann Oncol. 2025;36(2):208-215. PubMedDOI
    CiteLoading…
  102. Beets NRA, Verheij FS, Williams H, Omer DM, Lin ST, Qin LX, et al. Association of Lateral Pelvic Lymph Nodes with Disease Recurrence and Organ Preservation in Patients with Distal Rectal Adenocarcinoma Treated with Total Neoadjuvant Therapy. Ann Surg. 2025;282(2):311-318. PubMedDOI
    CiteLoading…
  103. Cercek A, Bachet JB, Capdevila J, Starling N, Chen E, Salvatore L, et al. A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1). Clin Colorectal Cancer. 2025;24(2):325-330. PubMedDOI
    CiteLoading…
  104. Cercek A, Foote MB, Rousseau B, Smith JJ, Shia J, Sinopoli J, et al. Nonoperative Management of Mismatch Repair-Deficient Tumors. N Engl J Med. 2025;392(23):2297-2308. PubMedDOI
    CiteLoading…
  105. Diefenhardt M, Kosmala R, Fleischmann M, Martin D, Hofheinz RD, Ghadimi M, et al. Chemotherapy before or after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer: 5-year results of the CAO/ARO/AIO-12 trial - a general pairwise comparison. ESMO Open. 2025;10(3):104483. PubMedDOI
    CiteLoading…
  106. Feng Q, Yuan W, Li T, Tang B, Jia B, Zhou Y, et al. Robotic vs Laparoscopic Surgery for Middle and Low Rectal Cancer: The REAL Randomized Clinical Trial. JAMA. 2025;334(2):136-148. PubMedDOI
    CiteLoading…
  107. Hofheinz RD, Fokas E, Benhaim L, Price TJ, Arnold D, Beets-Tan R, et al. Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36(9):1007-1024. PubMedDOI
  108. Jiang W, Xu J, Cui M, Qiu H, Wang Z, Kang L, et al. Laparoscopy-assisted versus open surgery for low rectal cancer (LASRE): 3-year survival outcomes of a multicentre, randomised, controlled, non-inferiority trial. Lancet Gastroenterol Hepatol. 2025;10(1):34-43. PubMedDOI
    CiteLoading…
  109. Sakai Y. Revisiting Japanese contributions to abdomino-perineal resection for rectal cancer. Surg Today. 2025;55(6):857-859. PubMedDOI
    CiteLoading…
  110. Serra-Aracil X, Pericay C, Cidoncha A, Badia-Closa J, Golda T, Kreisler E, et al. Chemoradiotherapy and Local Excision vs Total Mesorectal Excision in T2-T3ab, N0, M0 Rectal Cancer: The TAUTEM Randomized Clinical Trial. JAMA Surg. 2025;160(7):783-793. PubMedDOI
    CiteLoading…
  111. Tang Y, Li HY, Wei LC, Li N, Zhang WJ, Lu YF, et al. Short-course-based TNT with or without PD-1 inhibitor for pMMR locally advanced rectal cancer: Phase 2 results of a randomized trial (STELLAR II). Med. 2025;6(11):100807. PubMedDOI
    CiteLoading…
  112. Zeng Z, Luo S, Zhang H, Wu M, Ma D, Wang Q, et al. Transanal vs Laparoscopic Total Mesorectal Excision and 3-Year Disease-Free Survival in Rectal Cancer: The TaLaR Randomized Clinical Trial. JAMA. 2025;333(9):774-783. PubMedDOI
    CiteLoading…
  113. Bach SP, Sebag-Montefiore D, Homer V, Gilbert A, Appelt A, Geh I, et al. Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial. Lancet Oncol. 2026;27(9):1120-1132. PubMedDOI
    CiteLoading…
  114. Brown KGM, Stevenson ARL, Solomon MJ, Murray J, Wilson K, Gebski V, et al. Laparoscopic versus open surgery for rectal cancer: individual patient data meta-analysis of the ALaCaRT and Z6051 randomized trials. BJS Open. 2026;10(4). PubMedDOI
    CiteLoading…
  115. Cremolini C, Chalabi M, Elez E, Fassan M, Gelli M, Goéré D, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2026;37(6):759-776. PubMedDOI
  116. ClinicalTrials.gov. NCT00003422 (MRC CR07 / NCIC-CTG C016). Registry record, accessed 22 October 2026. NCT00003422
  117. ClinicalTrials.gov. NCT00058474 (NSABP R-04). Registry record, accessed 22 October 2026. NCT00058474
  118. ClinicalTrials.gov. NCT00145769 (TROG 01.04). Registry record, accessed 22 October 2026. NCT00145769
  119. ClinicalTrials.gov. NCT03875781 (NORAD01). Registry record, API v2, accessed 22 October 2026. NCT03875781
  120. ClinicalTrials.gov. NCT04246684 (ACO/ARO/AIO-18.1). Registry record, API v2, accessed 20 October 2026. NCT04246684
  121. ClinicalTrials.gov. NCT04749108 (GRECCAR 14). Registry record, API v2, accessed 22 October 2026. NCT04749108
  122. ClinicalTrials.gov. NCT04928807 (UNION). Registry record, accessed 22 October 2026. NCT04928807
  123. ClinicalTrials.gov. NCT05610163 (Janus Rectal Cancer Trial; Alliance A022104 / NRG-GI010). Registry record, API v2, accessed 22 October 2026. NCT05610163
  124. ClinicalTrials.gov. NCT05646511 (ENSEMBLE). Registry record, API v2, accessed 22 October 2026. NCT05646511
  125. ClinicalTrials.gov. NCT06229041 (TNTi). Registry record, API v2, accessed 22 October 2026. NCT06229041
  126. FDA. FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer. FDA notice, content current as of 19 October 2026. Source
  127. FDA. FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery. FDA news release, 19 October 2026. Source
  128. FDA. Prescribing information, Jemperli (dostarlimab-gxly) injection, labeling approved with BLA 761174/S-015 (revised 10/2026). Source
  129. FDA. Accelerated approval letter, BLA 761174/S-015 (Jemperli, dostarlimab-gxly; stage II/III MSI-H or dMMR locally advanced rectal cancer), e-signed 19 October 2026. Source
  130. GSK plc. Jemperli (dostarlimab-gxly) accepted for priority review by the US FDA for dMMR/MSI-H locally advanced rectal cancer. Stock-exchange announcement, Philadelphia, PA, 24 August 2026. Source
  131. ISRCTN registry. ISRCTN28785842: Pathology-guided treatment of rectal cancer: a randomised controlled trial (CR07). Registry record read through the ISRCTN public API, accessed 22 October 2026. Source
  132. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Cancer Stat Facts: Colorectal Cancer. Page accessed 20 October 2026; the page displays no update date (its HTTP Last-Modified header and last_modified meta tag read 22 April 2026). Source
  133. Tuynman JB, Yao H, Moolenaar LR, Sietses C, Hompes R, Aigner F, et al. Transanal total mesorectal excision versus laparoscopic total mesorectal excision for mid and low rectal cancer (COLOR III): short-term outcomes of an international, multicentre, phase 3, randomised, controlled, non-inferiority trial. Lancet Gastroenterol Hepatol. 2026;11(5):355-366. PubMedDOI
    CiteLoading…